ExodusPoint Capital Management’s Ginkgo Bioworks DNA Stock Holding History

ExodusPoint Capital Management’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$403K	Buy	+65,763	New	+$547K	﹤0.01%	1246
2024 Q3	–	Sell	-3,601	Closed	-$48K	–	1722
2024 Q2	$48K	Buy	+3,601	New	+$107K	﹤0.01%	1449
2023 Q3	–	Sell	-703	Closed	-$52K	–	1791
2023 Q2	$52K	Sell	703 -20,421	-97%	-$1.21M	﹤0.01%	1774
2023 Q1	$1.12M	Buy	+21,124	New	+$1.34M	0.01%	1104
2022 Q3	–	Sell	-7,099	Closed	-$676K	–	1968
2022 Q2	$676K	Sell	7,099 -12,176	-63%	-$1.49M	0.01%	1248
2022 Q1	$3.11M	Buy	19,275 +17,935	+1,338%	+$3.49M	0.04%	578
2021 Q4	$445K	Buy	+1,340	New	+$637K	﹤0.01%	1482

Other funds holding DNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.18B AUM 27.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ExodusPoint Capital Management's DNA Position: Q1 2026 in Review

ExodusPoint Capital Management opened a new position in Ginkgo Bioworks (DNA) in Q1 2026: 65,763 shares worth $403K. The stake represents ﹤0.01% of the portfolio and ranks #1246 among its holdings. This is a return to the name: ExodusPoint Capital Management previously reported a position in DNA as recently as Q2 2024.

ExodusPoint Capital Management first reported a position in DNA in Q4 2021 and has held it in 7 quarters since. The position peaked at $3.11M in Q1 2022. 174 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

ExodusPoint Capital Management held 65,763 shares of Ginkgo Bioworks worth $403K as of Q1 2026.
Ginkgo Bioworks was a new ExodusPoint Capital Management position in Q1 2026.
Ginkgo Bioworks made up ﹤0.01% of ExodusPoint Capital Management's portfolio in Q1 2026, its #1246 holding.
ExodusPoint Capital Management first reported a position in Ginkgo Bioworks in Q4 2021 and has held it in 7 quarters since.
ExodusPoint Capital Management's Ginkgo Bioworks position peaked at $3.11M in Q1 2022.
174 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.